Stocks

Cara Therapeutics: IDMC Recommends To Proceed KALM-1 Trial As Planned

(RTTNews.com) - Cara Therapeutics, Inc. ( CARA ) announced the completion of an interim statistical analysis of its pivotal KALM-1 Phase 3 trial of KORSUVA Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus. The company said, based on the recommendation of the Independent Data Monitoring Committee, the trial will continue as planned with no changes to the original enrollment target of 350 patients.

Derek Chalmers, CEO of Cara Therapeutics, said: "We are very pleased with the IDMC recommendation that the KALM-1 trial proceed as planned with no modifications, and we look forward to completing the study and reporting top-line data in the first half of this year."

The Phase 3 U.S. study is a multicenter, randomized, double-blind, placebo-controlled 12-week treatment trial (with a 52-week open label extension phase) that is designed to evaluate the safety and efficacy of 0.5 mcg/kg CR845/difelikefalin injection in 350 hemodialysis patients with moderate-to-severe pruritus.

Read the original article on RTTNews (http://www.rttnews.com/2966289/cara-therapeutics-idmc-recommends-to-proceed-kalm-1-trial-as-planned.aspx)

For comments and feedback: contact editorial@rttnews.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CARA

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More